The Royal Marsden Hospital NHS Foundation Trust, Gastrointestinal Trials Unit

Watch and Wait: Site feasibility checklist

1. Site and staff details

Site principal investigator:	
Site name:	
Site address:	
Name of Site study coordinator (responsible for obtaining local study approval and ongoing study administration):	
Designation:	
Telephone No.	
Fax No.	
Email address:	
Address:	
Site R&D Contact Name:	
Designation:	
Telephone No.	
Fax No.	
Email address:	
Address:	

•	Has the site participated in clinical trial-lf yes, please give study names:	als in rectal cancer?	Yes/No	
•	Have staff participated in studies in this tumour type previously? Yes/No -If so, approximately how many? Are investigators and research staff at the site familiar with conduct of clinical trials according to the principles of good clinical practice and United Kingdom law (SI 1031 of 2004, as amended by SI 1928 of 2006)?			
•	study have current GCP training, or a booked to attend a GCP course? Will a dedicated research nurse be a	I a dedicated research nurse be assigned to this study?		
•	-If yes, please provide name(s): Can a site log be maintained? Who will take patient consent?		Yes/No	
Name		Position		
•	Who will perform the study-related patient checks as detailed in the schedule of events? i.e. patient review, toxicity review and biochemical parameters?			
Name		Position		

Version 1	Version date 18.1.201	
sigmoidoscopy?	onal studies (MRI, PET-CT and flexible in of images to come to the Royal Marsden for den?	
	1 =	
Name	Position	
Who will coordinate patient care Name	on receipt of central imaging review? Position	
	me patient population which may potentially	
foreseeable future?	running at this site, either at present or in the	
 Considering the study eligibility criteria, any competing trials and patient numbers, how many patients will this site enrol: 		
Per month:		
 In total for the duration of the 	e trial (24 months):	
 Who is responsible for confirmin 	g that patient eligibility is accurate?	

Version 1 Version date 18.1.2010

Name	Position

3. Study procedures

• Study-related investigations including staging and assessment of tumour response: Are the following investigations, required by the trial, available at this site to the standard required by the study protocol?

•	CT thorax/abdomen/pelvis	Yes/No
•	Pelvic MRI	Yes/No
•	PET-CT	Yes/No
•	Flexible Sigmoidoscopy	Yes/No

- Can these be performed at the frequency requested in the schedule of events?
 Yes/No
- Who will assess tumour responses?

Name	Position	Are they experienced and familiar with RECIST?

•	Histopathology:
---	-----------------

•	Is there a named pathologist to be involved with this study? -If yes, please name:	Yes/No
-C	an CRFs be filled in by the histopathologist if required?	Yes/No

• Collection /Storage of Human Tissue:

- Does the site have experience in collection/storage of human tissue for translational components of trials?

 Yes/No
- Is there a -20 0C freezer?

Yes/No

- If yes who is responsible for maintaining it?

4	Data	reti	ırn:
╼.	$\boldsymbol{\nu}$ au		4111.

•	Please confirm that the site has adequate staff resources to ensure timely completion of case report forms, and prompt return of data and responses to data queries: Yes/No			
•	Who will complete and send in the CRFs?			
•	Is there a fax machine? -who maintains it?		Yes/No	
•	Who will sign off Serious Adverse Ev	rent Forms?		
Name		Position		
•	 Please confirm that site research staff will be able to assist with monitoring procedures required by the study Sponsor: Yes/No 			
•	Can all case report forms be sent at the end of the study back to the Sponsor fo archiving? Yes/No			
5. Standard operating procedures (SOPs): Please indicate if the site has SOPs or Guidance notes for the following:				
•	Obtaining local regulatory and ethica	l annroval:	Yes/No	
•	Maintenance of study site file and stu		Yes/No	
•	Informed consent for participation in	•	Yes/No	
Can copies of these SOPs be provided to the Sponsor of this study? Yes/No				
I confirm that as Principal Investigator, I have reviewed the study protocol and that I agree with the responses to the above questions:				
Signat	ture of PI:			
Name	of PI:	Date:		